Keywords: Alternatives to animal testing; QIVIVE; Regulatory acceptance; Food toxicology; Drivers and barriers; Multilevel perspective on technology transitions; 3R; replace, reduce, or refine; EFSA; European Food Safety Authority; EU; European Union; PBPK; physiol
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Biogenic amines; Red wine; Nationwide survey; PBPK;
Keywords: pKa; High throughput; Ionization; Volume of distribution; PBPK;
Keywords: Gastrointestinal volumes; Variability; Biorelevant dissolution; PBPK; Magnetic resonance imaging; Fasted stomach;
Keywords: CLint; Intrinsic hepatic clearance; HLM; Human liver microsomes; LC/MS/MS; Liquid chromatography tandem mass spectrometry; LC/UV/RAD; Liquid chromatography/ultraviolet/radioactive detection; MRM; Multiple reaction monitoring; NADPH; Nicotinamide adenine d
Keywords: fraction absorbed; pharmacokinetics; PBPK; absorption; absorption efficiency; %Fa; modeling;
Keywords: Drug delivery; Aerosol; Deposition; Dissolution; Permeation; Respiratory; PBPK;
Keywords: BCRP; breast cancer resistant protein; BSEP; bile salt efflux pump; GA; gestational age; GLUT1; glucose transporter 1; MCT1; monocarboxylate transporter 1; MDR; multidrug-resistance protein; MRP; multidrug-resistance like protein; NTCP; Na+-taurocholate c
Keywords: AAG; α1-acid glycoprotein; IPRL; isolated perfused rat liver; IVIVE; in vitro-in vivo extrapolation; PBPK; physiologically based pharmacokinetic(s); PK; pharmacokinetic(s); Pharmacokinetics; Well-stirred model; Parallel-tube model; Dispersion model; Hepa
Keywords: Bayesian analysis; Glutathione conjugation; Oxidative metabolism; Tetrachloroethylene; Physiologically based pharmacokinetic (PBPK) model; Risk assessment; CC; Collaborative Cross; CDC; Centers for Disease Control and Prevention; CU; coefficient of uncert
Keywords: ADAM; advanced dissolution, absorption, and metabolism; AED; antiepileptic drug; AUC; area-under-the-curve; B/P; blood to plasma ratio; BID; twice daily; BMI; body mass index; CBZ; carbamazepine; CLint; intrinsic clearance; CLR; renal clearance; CL; clear
Quantitative estimation of cholinesterase-specific drug metabolism of carbamate inhibitors provided by the analysis of the area under the inhibition-time curve
Keywords: AChE; acetylcholinesterase (EC 3.1.1.7); ADME; absorption, distribution, metabolism, excretion; AUC; area under the concentration-time curve; AUIC; area under the inhibition-time curv; BChE; butyrylcholinesterase (EC 3.1.1.8); BTCh; butyrylthiocholine; DT
Keywords: Exposure; Risk assessment; 3Rs; (Toxico)kinetics; PBPK; Regulatory;
Keywords: KNIME; Virtual cell based assay; Physiologically based kinetic models; PBPK; Toxicity; Automated workflows;
Keywords: Berkeley-Madonna; Dioxin; PBPK; Risk assessment;
Keywords: Quantitative bias analysis; PFOS; PFOA; PBPK; Menopause; Female;
Keywords: PFOA; PBPK; Human; Monte Carlo;
Keywords: Benzoic acid; Food additive; Metabolism; PBPK; Exposure assessment; Ingredient safety;
Keywords: biliary excretion; drug interactions; efflux pumps; MRP; permeability; ATV; atorvastatin; MET; metformin; 2-OH ATV; 2-hydroxyatorvastatin; CYP; cytochrome P450; MDCK; Madin-Darby canine kidney; MDR; multidrug resistance gene; BCRP; breast cancer resistanc
Keywords: physiologically based pharmacokinetic modelling; PBPK; monoclonal antibody; therapeutic proteins;
Keywords: albumin; mathematical model; pharmacokinetics; protein binding; organic anion-transporting polypeptide transporters; food effects; hepatic transport; nonlinear pharmacokinetics; clinical pharmacokinetics; ADME; BA; bioavailability; BCS; biopharmaceutica
Keywords: preclinical pharmacokinetics; physiological model; simulations; clearance; absorption; distribution; ADAM; advanced dissolution absorption and metabolism; B:P; blood-to-plasma ratio; CLint; intrinsic clearance; CLiv; intravenous clearance; CLu,intH; unbou
Keywords: AD; Alzheimer disease; ADME; absorption, distribution, metabolism and excretion; AO; adverse outcome; AOP; adverse outcome pathway; AOP-KB; adverse outcome pathway knowledge base; BDNF; brain derived neurotrophic factor; B/H; Bradford-Hill; CI; complex I
Keywords: Margin of safety; MOS; Manganese; PBPK; Pharmacokinetics;
Keywords: physiologically based pharmacokinetic modeling; transporters; hepatobiliary disposition; hepatic metabolism; mathematical model; AUC; area under the concentration-time curve; Cmax; maximum plasma concentration; CYP; cytochrome P450 enzyme; CL; clearance;
Keywords: physiologically based pharmacokinetic modeling; drug interactions; Monte Carlo; in vitro-in vivo correlations (IVIVC); nonlinear regression; biliary excretion; biliary recycling; hepatic metabolism; hepatic transport; AUC; area under the curve of concen
Keywords: pulmonary; tissue partition; pharmacokinetics; pulmonary drug delivery; distribution; Cu,cell; intracellular unbound drug concentration; Cu,lungISF; unbound drug concentration in the lung interstitial fluid; fu,lung; fraction of unbound drug in diluted lu
Keywords: PFOA; PFOS; PBPK; Menarche; Female; Environmental exposure
Keywords: Physiologically based pharmacokinetics model; Pharmacokinetics; Bayesian inference; Robust parameter estimation; Tegafur; 5-fluorouracil; PBPK; physiologically based pharmacokinetic; DDM; drug dissolution model; MLE; maximum likelihood estimation; MAP; ma
Keywords: Perchlorate; Iodide; PBPK modeling; Thyroid hormones; DWEL; Drinking Water Equivalent Level; EPA; US Environmental Protection Agency; FDA; US Food and Drug Administration; fT4; free thyroxine levels; HPT; hypothalamic pituitary thyroid; NHANES; National H
Keywords: 5α-R; 5α-reductase type 2; ADME; absorption, distribution, metabolism and excretion; AG; andrographolide; AGD; anogenital distance; AOP; adverse outcome pathway; AR; androgen receptor; BPAD; biological pathway altering dose; CHH; congenital hypogonadotr
Keywords: PFOA; PBPK; Oatp1a1; Oat1; Oat3; IVIVE
Keywords: AMI; amiodarone; MDEA; mono-N-desethylamiodarone; DDEA; di-N-desethylamiodarone; PHH; primary human hepatocytes; CYP; cytochrome P450; DMSO; dimetylsulfoxide; MeOH; methanol; HMM; Hepatocyte Maintenance Medium; FCS; fetal calf serum; SW; sandwich; d0; day
Keywords: AUC; area under the curve; BPA; bisphenol A; BUP; bitumen upgrading product; BR; bayrepel; CAP; trans-capsaicin; COM; complex organic mixture; CSO; clarified slurry oil; DAE; distillate aromatic extract; DDT; dichlorodiphenyltrichloroethane; DEET; N,N-Die
Keywords: Microdialysis; Humans; Data analysis; NLME; PBPK; Population PBPK;
Keywords: Valproic acid; Pharmacokinetics; Dravet syndrome; Epilepsy; PBPK; Modelling
Keywords: ADME; absorption, distribution, metabolism, elimination; ATUS; American Time Use Survey; BE; biomonitoring equivalent; BEPOD; biomonitoring equivalent corresponding to the point of departure; BW; body weight; CDC; Centers for Disease Control and Preventio
Keywords: Biopharmaceutics; Biopharmaceutical classification system; PBPK; IVIVC; Dissolution; Drug absorption;
Keywords: SPM; Polycyclic aromatic hydrocarbons; PBPK; PBTK; Bioconcentration factor;
Keywords: CL; lumen Cr concentration; Cr; chromium; Cr(III); trivalent chromium; Cr(VI); hexavalent chromium; GI; gastrointestinal; KM; Michaelis-Menten constant; KRED; Rate constant for Cr(VI) reduction; L; Small intestines section length; PBPK; physiologically
Keywords: Methyl methacrylate; Olfactory effects; Human relevance; Occupational levels; Physiologically based pharmacokinetic (PBPK) model; Dosimetric adjustment factors; 2-EH; 2-ethyl Hexanol; AA; acrylic acid; ACGIH; American Conference of Governmental Industrial
Keywords: AUC; area under the curve; BW; body weight; Cant50; tolerance “concentration”; CLKC; nicotine renal clearance; CLMC; nicotine metabolic clearance; COTCL; total cotinine clearance (unscaled); COTCLC; total cotinine clearance (scaled); CVVB; blood nicot
Keywords: ABC; ATP-binding cassette; ATR; atrazine, 2-chloro-4-(ethylamino)-6-(isopropylamino)-s-triazine; AUC; area under the curve; BW; body weight; 14C-ATR; 14C-atrazine; DACT; didealkylatrazine, 2-chloro-4,6-diamino-1,3,5-triazine; DE; desethylatrazine, 2-chlor
Feasibility of using urinary TDGA as a biomarker for VCM exposures
Keywords: TDGA; PBPK; Signal; Biomarker; VCM; Risk assessment;
Prenatal contribution of 2, 2â², 4, 4â²-tetrabromodiphenyl ether (BDE-47) to total body burden in young children
Keywords: 2,2â²,4,4â²-tetrabromodiphenyl ether (BDE-47); Placental transfer; PBPK; Exposure assessment; Innate amounts;
Introduction to the OrBiTo decision tree to select the most appropriate in vitro methodology for release testing of solid oral dosage forms during development
Keywords: Dissolution; Decision tree; Formulation; Oral absorption; PBPK; Biopharmaceutics classification system (BCS);
Excretion of Di-2-ethylhexyl phthalate (DEHP) metabolites in urine is related to body mass index because of higher energy intake in the overweight and obese
Keywords: Diethylhexyl phthalate; PBPK; Quantitative bias analysis; Obesogens;
The Seveso accident: A look at 40â¯years of health research and beyond
Keywords: BMI; body mass index; CDC; Centers for Disease Control and Prevention; DXA; dual-energy X-ray absorptiometry; EPIC; European Prospective Investigation into Cancer and Nutrition; IARC; International Agency for Research on Cancer; IHD; ischemic heart diseas
In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants
Keywords: AUC; area under the plasma concentration vs. time curve; CL; total body clearance; P450; general term for cytochrome P450 (EC 1.14.14.1); V; volume of distribution; Marmoset; CYP3A4; CYP2C19; Polymorphism; PBPK;
Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products
Keywords: Virtual bioequivalence; Carvedilol; In vitro-in silico-in vivo; PBPK;